Puma Biotechnology Announced Presentation of Findings From Phase II Study Of Alisertib In Endocrine-Resistant Metastatic Breast Cancer ASCO 2024
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the